FDA grants orphan drug designation to novel bispecific antibody for pancreatic cancer
The FDA granted orphan drug designation to ATG-101 for the treatment of pancreatic cancer, according to a press release from the agent’s manufacturer.ATG-101 (Antengene), a novel PD-L1/4-1BB bispecific antibody, has been designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, causing activation of antitumor immune effectors and conferring enhanced antitumor activity, according to an Antengene press release. The agent has shown significant antitumor activity in animal models of resistant tumors and those that progressed on anti-PD-1/PD-L1Read More
